Perspectiva global sobre los datos de tratamientos emergentes con inhibidores de TQB para LLC y LCM en recidiva/refractarios en 2022

Content Format:

Text Module

Credit Type:

--

Credits:

--
Uma perspectiva global sobre os dados emergentes da terapia com inibidor de BTK para LLC e LCM recidivantes/refratários em 2022

Content Format:

Text Module

Credit Type:

--

Credits:

--
Une perspective globale sur les données émergentes relatives à la thérapie par inhibiteurs BTK chez les patients atteints de LLC ou du LCM récidivant/réfractaire en 2022

Content Format:

Text Module

Credit Type:

--

Credits:

--
A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.00
Cancer Conversations: BTK Inhibitor Therapies for CLL/SLL and MCL in 2022

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

1.00
Einblicke in neue Daten zu BTK-Inhibitoren bei CLL und MCL aus der Pan Pacific Lymphoma Conference 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Approfondimenti sui nuovi dati relativi agli inibitori di BTK per la CLL e lMCL emersi dalla Conferenza Pan Pacific Lymphoma del 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Aperçu des nouvelles données sur les inhibiteurs de la BTK pour le traitement de la LLC et du LCM lors de la Pan Pacific Lymphoma Conference de 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Insights on New Data With BTK Inhibitors for CLL and MCL From the 2022 Pan Pacific Lymphoma Conference

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Podcast Pearls: Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL

Content Format:

PDF

Credit Type:

--

Credits:

--
Addressing Evolving Educational Needs on BTK Inhibitor Therapies in CLL/SLL and MCL

Content Format:

Multimedia

Credit Type:

AMA

Credits:

1.00
Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
BTK Inhibitor Therapies in CLL/SLL and MCL

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
ExpressPoints: BTK Inhibitor Therapies in CLL/SLL and MCL

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Cases in CLL: High-Risk Patient Requiring First-line Therapy

Content Format:

Multimedia

Credit Type:

AANP | ACPE | AMA

Credits:

0.25
Cases in CLL Slides: High-Risk Patient Requiring First-line Therapy

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Cases in CLL Slides: Second-Line Therapy Following Chemoimmunotherapy

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Insights sobre novos dados com inibidores de BTK para LLC e LCM da edição 2022 da Conferência Pan-Pacífico sobre Linfomas (Pan Pacific Lymphoma Conference)

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Conclusiones sobre los nuevos datos relativos a los inhibidores de la TQB para LLC y LCM de la Conferencia del Pacífico sobre el Linfoma de 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--